Apogee Therapeutics Files 8-K
Ticker: APGE · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1974640
| Field | Detail |
|---|---|
| Company | Apogee Therapeutics, Inc. (APGE) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, filing
Related Tickers: APOG
TL;DR
APOG filed an 8-K, standard disclosure stuff.
AI Summary
On October 24, 2024, Apogee Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates Apogee Therapeutics is providing required disclosures and financial information to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any specific new risks or material events.
Key Players & Entities
- Apogee Therapeutics, Inc. (company) — Registrant
- October 24, 2024 (date) — Date of earliest event reported
- Waltham, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Apogee Therapeutics, Inc.?
The filing is for Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Apogee Therapeutics, Inc.
On what date was the earliest event reported in this filing?
The earliest event reported was on October 24, 2024.
What is the principal executive office address of Apogee Therapeutics, Inc.?
The principal executive office is located at 221 Crescent Street, Building 17, Suite 102b, Waltham, MA, 02453.
What is the Commission File Number for Apogee Therapeutics, Inc.?
The Commission File Number is 001-41740.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-10-24 08:10:13
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share APGE The Nasdaq Global Ma
Filing Documents
- tm2426705d1_8k.htm (8-K) — 26KB
- tm2426705d1_ex99-1.htm (EX-99.1) — 19KB
- tm2426705d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-111027.txt ( ) — 230KB
- apge-20241024.xsd (EX-101.SCH) — 3KB
- apge-20241024_lab.xml (EX-101.LAB) — 33KB
- apge-20241024_pre.xml (EX-101.PRE) — 22KB
- tm2426705d1_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On October 24, 2024, Apogee Therapeutics, Inc. (the "Company") issued a press release announcing results up to nine months from its Phase 1 clinical trial of APG777. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The following exhibit is being furnished herewith: EXHIBIT INDEX Exhibit No. Description 99.1 Press Release, dated October 24, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apogee Therapeutics, Inc. Date: October 24, 2024 By: /s/ Michael Henderson, M.D. Name: Michael Henderson, M.D. Title: Chief Executive Officer